Healthy China 2030 reforms: A balance of opportunities and risks for investors

Country has introduced healthcare reforms

With the 'Healthy China 2030' programme underway, the Chinese government is aiming to improve healthcare quality and affordability across the nation through reformed legislation and institutional reorganisation.

These reforms are transforming the country's drug innovation and healthcare ecosystem, offering enticing opportunities for investors although there are some risks to watch out for. Supported by an ageing population, rising disposable income and commercial insurance, healthcare spending in China remains robust and we expect it to grow at a 10% compound annual growth rate (CAGR) over the next 10 years. The recent years' reforms are enabling more innovative drugs and therapies to be approved faster than ever before. China now has an increasingly competitive medical devices and biotech...